癌症研究
巨噬细胞极化
免疫系统
生物
肿瘤微环境
结直肠癌
脂质代谢
癌细胞
炎症
巨噬细胞
细胞
癌变
细胞生物学
转录组
癌症
肿瘤进展
细胞毒性
转染
先天免疫系统
免疫原性细胞死亡
免疫学
微泡
信号转导
细胞培养
作者
Lingzhen Jiang,C J Li,Peng Teng,Qin Yan,Junhui Tang,Xiaohui Hu,Y Li,Feiyu Qin,Surui Yao,Xiaowei Qi,Zhaohui Huang,Yuan Yin
标识
DOI:10.1038/s41419-026-09007-2
摘要
Dysregulated metabolism and functions of immune cells in the tumor microenvironment (TME) are key factors contributing to cancer progression. As the core immune cells in TME, tumor-associated macrophages (TAMs) have become a central focus in metabolic research of TME, though underlying mechanisms are not fully elucidated. Here, we found that long-chain acyl-coenzyme A synthetase-3 (ACSL3) is highly expressed in TAMs and correlates with poor prognosis in colorectal cancer (CRC). ACSL3 depletion induces TAM ferroptosis and reprograms them toward an M1-like phenotype. We further revealed that ACSL3 undergoes lactylation in TAMs, and identified Sirtuin 7 (SIRT7) as its delactylase. Mechanistically, SIRT7 delactylates ACSL3 at lysine 679, restores its enzymatic function and reprograms lipid metabolism in TAMs. Importantly, lactylated and activated ACSL3 significantly protects TAMs from ferroptotic stress and sustains their immunosuppressive phenotype. On the contrary, inhibiting ACSL3 lactylation reprograms TAMs toward an M1-like phenotype, further restores T cell cytotoxicity and suppresses CRC progression. Collectively, these findings establish ACSL3 lactylation in TAMs as a crucial signaling event that enables ferroptosis resistance and maintains M2 polarization, thereby promoting CRC progression. This study provides the therapeutic potential of targeting SIRT7-mediated delactylation of ACSL3 in TAMs, offering a promising strategy for CRC therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI